Published in Cell Commun Signal on August 28, 2013
Adrenoreceptors and nitric oxide in the cardiovascular system. Front Physiol (2013) 0.95
Adrenergic signaling and oxidative stress: a role for sirtuins? Front Physiol (2013) 0.93
Effects of exercise training on cardiovascular adrenergic system. Front Physiol (2013) 0.88
Adrenal adrenoceptors in heart failure. Front Physiol (2014) 0.85
Pathophysiology of sepsis-related cardiac dysfunction: driven by inflammation, energy mismanagement, or both? Curr Heart Fail Rep (2015) 0.84
Prognostic Value of Lymphocyte G Protein-Coupled Receptor Kinase-2 Protein Levels in Patients With Heart Failure. Circ Res (2016) 0.80
Neuro-hormonal effects of physical activity in the elderly. Front Physiol (2013) 0.79
βArrestins in cardiac G protein-coupled receptor signaling and function: partners in crime or "good cop, bad cop"? Int J Mol Sci (2013) 0.79
Molecular Mechanisms Linking Autonomic Dysfunction and Impaired Cardiac Contractility in Critical Illness. Crit Care Med (2016) 0.77
Analyzing the roles of multi-functional proteins in cells: The case of arrestins and GRKs. Crit Rev Biochem Mol Biol (2015) 0.77
β2-adrenoceptor signaling reduction in dendritic cells is involved in the inflammatory response in adjuvant-induced arthritic rats. Sci Rep (2016) 0.77
Effects of paroxetine-mediated inhibition of GRK2 expression on depression and cardiovascular function in patients with myocardial infarction. Neuropsychiatr Dis Treat (2016) 0.75
Structure-activity relationship study of angiotensin II analogs in terms of β-arrestin-dependent signaling to aldosterone production. Pharmacol Res Perspect (2016) 0.75
Targeting β3-Adrenergic Receptors in the Heart: Selective Agonism and β-Blockade. J Cardiovasc Pharmacol (2017) 0.75
β 1 Adrenoceptor antagonistic effects of the supposedly selective β 2 adrenoceptor antagonist ICI 118,551 on the positive inotropic effect of adrenaline in murine hearts. Pharmacol Res Perspect (2015) 0.75
cAMP-PKA-CaMKII signaling pathway is involved in aggravated cardiotoxicity during Fuzi and Beimu Combination Treatment of Experimental Pulmonary Hypertension. Sci Rep (2016) 0.75
G-protein coupled receptor kinase-2 is a critical regulator of TNFα signaling in colon epithelial cells. Biochem J (2017) 0.75
Beta-arrestins and cell signaling. Annu Rev Physiol (2007) 8.65
Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu Rev Biochem (2007) 5.62
Seven-transmembrane-spanning receptors and heart function. Nature (2002) 5.38
Switching of the coupling of the beta2-adrenergic receptor to different G proteins by protein kinase A. Nature (1997) 5.31
Altered expression of beta-adrenergic receptor kinase and beta 1-adrenergic receptors in the failing human heart. Circulation (1993) 4.52
Cardiac function in mice overexpressing the beta-adrenergic receptor kinase or a beta ARK inhibitor. Science (1995) 4.18
Early and delayed consequences of beta(2)-adrenergic receptor overexpression in mouse hearts: critical role for expression level. Circulation (2000) 3.85
The NF-kappa B activation pathway: a paradigm in information transfer from membrane to nucleus. Sci STKE (1999) 3.79
PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. Biochem J (2003) 3.43
Cell death in the pathogenesis of heart disease: mechanisms and significance. Annu Rev Physiol (2010) 3.16
Beta2-adrenergic receptor redistribution in heart failure changes cAMP compartmentation. Science (2010) 2.99
The beta(2)-adrenergic receptor delivers an antiapoptotic signal to cardiac myocytes through G(i)-dependent coupling to phosphatidylinositol 3'-kinase. Circ Res (2000) 2.99
Compartmentation of cyclic nucleotide signaling in the heart: the role of cyclic nucleotide phosphodiesterases. Circ Res (2006) 2.59
Dual modulation of cell survival and cell death by beta(2)-adrenergic signaling in adult mouse cardiac myocytes. Proc Natl Acad Sci U S A (2001) 2.52
Opposing effects of beta(1)- and beta(2)-adrenergic receptors on cardiac myocyte apoptosis : role of a pertussis toxin-sensitive G protein. Circulation (1999) 2.50
Adrenal GRK2 upregulation mediates sympathetic overdrive in heart failure. Nat Med (2007) 2.48
beta-Arrestin-mediated PDE4 cAMP phosphodiesterase recruitment regulates beta-adrenoceptor switching from Gs to Gi. Proc Natl Acad Sci U S A (2003) 2.43
Coupling of beta2-adrenoceptor to Gi proteins and its physiological relevance in murine cardiac myocytes. Circ Res (1999) 2.37
Identification of beta-arrestin2 as a G protein-coupled receptor-stimulated regulator of NF-kappaB pathways. Mol Cell (2004) 2.37
G protein-coupled receptor kinase 2 ablation in cardiac myocytes before or after myocardial infarction prevents heart failure. Circ Res (2008) 2.22
CaMK4 Gene Deletion Induces Hypertension. J Am Heart Assoc (2012) 2.14
Cardiac-specific ablation of G-protein receptor kinase 2 redefines its roles in heart development and beta-adrenergic signaling. Circ Res (2006) 2.08
Targeted disruption of the mouse beta1-adrenergic receptor gene: developmental and cardiovascular effects. Proc Natl Acad Sci U S A (1996) 2.02
beta-Arrestin inhibits NF-kappaB activity by means of its interaction with the NF-kappaB inhibitor IkappaBalpha. Proc Natl Acad Sci U S A (2004) 1.91
Beta-adrenergic receptor subtype-specific signaling in cardiac myocytes from beta(1) and beta(2) adrenoceptor knockout mice. Mol Pharmacol (2001) 1.90
Low- and high-level transgenic expression of beta2-adrenergic receptors differentially affect cardiac hypertrophy and function in Galphaq-overexpressing mice. Proc Natl Acad Sci U S A (1999) 1.85
Myocyte adrenoceptor signaling pathways. Science (2003) 1.81
Nuclear factor kappa-B and the heart. J Am Coll Cardiol (2001) 1.68
Phosphodiesterase 4D is required for beta2 adrenoceptor subtype-specific signaling in cardiac myocytes. Proc Natl Acad Sci U S A (2005) 1.65
Level of G protein-coupled receptor kinase-2 determines myocardial ischemia/reperfusion injury via pro- and anti-apoptotic mechanisms. Circ Res (2010) 1.52
Signaling from beta1- and beta2-adrenergic receptors is defined by differential interactions with PDE4. EMBO J (2008) 1.50
Intracardiac injection of AdGRK5-NT reduces left ventricular hypertrophy by inhibiting NF-kappaB-dependent hypertrophic gene expression. Hypertension (2010) 1.47
Control of myocardial contractile function by the level of beta-adrenergic receptor kinase 1 in gene-targeted mice. J Biol Chem (1998) 1.42
Subtype-specific beta-adrenoceptor signaling pathways in the heart and their potential clinical implications. Trends Pharmacol Sci (2004) 1.38
GRK2 as a novel gene therapy target in heart failure. J Mol Cell Cardiol (2010) 1.31
Protecting the myocardium: a role for the beta2 adrenergic receptor in the heart. Crit Care Med (2004) 1.28
Differential cardioprotective/cardiotoxic effects mediated by beta-adrenergic receptor subtypes. Am J Physiol Heart Circ Physiol (2005) 1.21
Beta1-adrenergic receptors stimulate cardiac contractility and CaMKII activation in vivo and enhance cardiac dysfunction following myocardial infarction. Am J Physiol Heart Circ Physiol (2009) 1.17
Novel therapeutic targets for the treatment of heart failure. Nat Rev Drug Discov (2011) 1.17
The enigma of beta2-adrenergic receptor Gi signaling in the heart: the good, the bad, and the ugly. Circ Res (2005) 1.15
G protein coupled receptor kinases as therapeutic targets in cardiovascular disease. Circ Res (2011) 1.14
Class A scavenger receptor attenuates myocardial infarction-induced cardiomyocyte necrosis through suppressing M1 macrophage subset polarization. Basic Res Cardiol (2011) 1.14
Signal transduction through nuclear factor kappa B in ischemia-reperfusion and heart failure. Basic Res Cardiol (2003) 1.08
Differential association of phosphodiesterase 4D isoforms with beta2-adrenoceptor in cardiac myocytes. J Biol Chem (2009) 1.08
Cardiac-specific overexpression of human beta2 adrenoceptors in mice exposes coupling to both Gs and Gi proteins. Br J Pharmacol (2003) 1.06
Future g protein-coupled receptor targets for treatment of heart failure. Curr Treat Options Cardiovasc Med (2009) 0.97
Generation and characterization of a mouse model of the metabolic syndrome: apolipoprotein E and aromatase double knockout mice. Am J Physiol Endocrinol Metab (2011) 0.89
Involvement of nuclear factor κB (NF-κB) signaling pathway in regulation of cardiac G protein-coupled receptor kinase 5 (GRK5) expression. J Biol Chem (2012) 0.87
Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. Mol Ther (2008) 5.83
Seven-transmembrane-spanning receptors and heart function. Nature (2002) 5.38
A GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure. Nat Med (2008) 3.98
Genetic alterations that inhibit in vivo pressure-overload hypertrophy prevent cardiac dysfunction despite increased wall stress. Circulation (2002) 3.15
A novel and efficient model of coronary artery ligation and myocardial infarction in the mouse. Circ Res (2010) 3.00
Regulation of beta-adrenergic receptor signaling by S-nitrosylation of G-protein-coupled receptor kinase 2. Cell (2007) 2.65
Adrenal GRK2 upregulation mediates sympathetic overdrive in heart failure. Nat Med (2007) 2.48
A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest (2003) 2.32
Animal models of heart failure: a scientific statement from the American Heart Association. Circ Res (2012) 2.31
Elevated myocardial and lymphocyte GRK2 expression and activity in human heart failure. Eur Heart J (2005) 2.29
Adiponectin cardioprotection after myocardial ischemia/reperfusion involves the reduction of oxidative/nitrative stress. Circulation (2007) 2.28
G protein-coupled receptor kinase 2 ablation in cardiac myocytes before or after myocardial infarction prevents heart failure. Circ Res (2008) 2.22
Effects of type 2 diabetes mellitus on coronary microvascular function and myocardial perfusion in patients without obstructive coronary artery disease. Eur J Nucl Med Mol Imaging (2012) 2.17
Myocardial adeno-associated virus serotype 6-betaARKct gene therapy improves cardiac function and normalizes the neurohormonal axis in chronic heart failure. Circulation (2008) 2.17
Hyperphosphorylation of the cardiac ryanodine receptor at serine 2808 is not involved in cardiac dysfunction after myocardial infarction. Circ Res (2012) 2.16
Nitric oxide mediates the antiapoptotic effect of insulin in myocardial ischemia-reperfusion: the roles of PI3-kinase, Akt, and endothelial nitric oxide synthase phosphorylation. Circulation (2002) 2.14
Differential gene expression and genomic patient stratification following left ventricular assist device support. J Am Coll Cardiol (2003) 2.08
Cardiac-specific ablation of G-protein receptor kinase 2 redefines its roles in heart development and beta-adrenergic signaling. Circ Res (2006) 2.08
Uncovering G protein-coupled receptor kinase-5 as a histone deacetylase kinase in the nucleus of cardiomyocytes. Proc Natl Acad Sci U S A (2008) 1.93
C1q/tumor necrosis factor-related protein-3, a newly identified adipokine, is a novel antiapoptotic, proangiogenic, and cardioprotective molecule in the ischemic mouse heart. Circulation (2012) 1.90
Negative impact of β-arrestin-1 on post-myocardial infarction heart failure via cardiac and adrenal-dependent neurohormonal mechanisms. Hypertension (2013) 1.83
Multidimensional Prognostic Index based on a comprehensive geriatric assessment predicts short-term mortality in older patients with heart failure. Circ Heart Fail (2009) 1.83
Gene therapy in heart failure. Circ Res (2008) 1.79
Cardioprotective effects of thioredoxin in myocardial ischemia and reperfusion: role of S-nitrosation [corrected]. Proc Natl Acad Sci U S A (2004) 1.76
Pharmacological- and gene therapy-based inhibition of protein kinase Calpha/beta enhances cardiac contractility and attenuates heart failure. Circulation (2006) 1.73
Biology of intracranial aneurysms: role of inflammation. J Cereb Blood Flow Metab (2012) 1.73
Stable myocardial-specific AAV6-S100A1 gene therapy results in chronic functional heart failure rescue. Circulation (2007) 1.73
S100A1 genetically targeted therapy reverses dysfunction of human failing cardiomyocytes. J Am Coll Cardiol (2011) 1.68
Physical training increases eNOS vascular expression and activity and reduces restenosis after balloon angioplasty or arterial stenting in rats. Circ Res (2002) 1.67
β-Adrenergic regulation of cardiac progenitor cell death versus survival and proliferation. Circ Res (2012) 1.66
AMP-activated protein kinase deficiency enhances myocardial ischemia/reperfusion injury but has minimal effect on the antioxidant/antinitrative protection of adiponectin. Circulation (2009) 1.65
Cardiac S100A1 protein levels determine contractile performance and propensity toward heart failure after myocardial infarction. Circulation (2006) 1.64
Adrenergic nervous system in heart failure: pathophysiology and therapy. Circ Res (2013) 1.62
Obstructive sleep apnea syndrome affects liver histology and inflammatory cell activation in pediatric nonalcoholic fatty liver disease, regardless of obesity/insulin resistance. Am J Respir Crit Care Med (2014) 1.60
β-arrestin1-biased β1-adrenergic receptor signaling regulates microRNA processing. Circ Res (2013) 1.59
Cardiac adenoviral S100A1 gene delivery rescues failing myocardium. J Clin Invest (2004) 1.58
Ischemic neoangiogenesis enhanced by beta2-adrenergic receptor overexpression: a novel role for the endothelial adrenergic system. Circ Res (2005) 1.57
Targeted inhibition of cardiomyocyte Gi signaling enhances susceptibility to apoptotic cell death in response to ischemic stress. Circulation (2008) 1.56
Inhibition of the cardiomyocyte-specific kinase TNNI3K limits oxidative stress, injury, and adverse remodeling in the ischemic heart. Sci Transl Med (2013) 1.55
Cardiac AAV9-S100A1 gene therapy rescues post-ischemic heart failure in a preclinical large animal model. Sci Transl Med (2011) 1.54
Induction of mitogen-activated protein kinases is proportional to the amount of pressure overload. Hypertension (2009) 1.53
Level of G protein-coupled receptor kinase-2 determines myocardial ischemia/reperfusion injury via pro- and anti-apoptotic mechanisms. Circ Res (2010) 1.52
Cardiac G-protein-coupled receptor kinase 2 ablation induces a novel Ca2+ handling phenotype resistant to adverse alterations and remodeling after myocardial infarction. Circulation (2012) 1.52
Direct evidence of intracrine angiotensin II signaling in neurons. Am J Physiol Cell Physiol (2014) 1.51
Downregulation of adiponectin induced by tumor necrosis factor α is involved in the aggravation of posttraumatic myocardial ischemia/reperfusion injury. Crit Care Med (2011) 1.50
Angiotensin II-receptor antagonist losartan does not prevent nitroglycerin tolerance in patients with coronary artery disease. Cardiovasc Drugs Ther (2004) 1.43
Transgenic overexpression of the Ca2+-binding protein S100A1 in the heart leads to increased in vivo myocardial contractile performance. J Biol Chem (2003) 1.43
Blockade of NOX2 and STIM1 signaling limits lipopolysaccharide-induced vascular inflammation. J Clin Invest (2013) 1.40
Exercise training promotes SIRT1 activity in aged rats. Rejuvenation Res (2008) 1.40
Vascular-targeted overexpression of G protein-coupled receptor kinase-2 in transgenic mice attenuates beta-adrenergic receptor signaling and increases resting blood pressure. Mol Pharmacol (2002) 1.38
AAV6.βARKct cardiac gene therapy ameliorates cardiac function and normalizes the catecholaminergic axis in a clinically relevant large animal heart failure model. Eur Heart J (2012) 1.35
Glycogen synthase kinase-3beta regulates post-myocardial infarction remodeling and stress-induced cardiomyocyte proliferation in vivo. Circ Res (2010) 1.33
Reduction of sympathetic activity via adrenal-targeted GRK2 gene deletion attenuates heart failure progression and improves cardiac function after myocardial infarction. J Biol Chem (2010) 1.32
Role of Omi/HtrA2 in apoptotic cell death after myocardial ischemia and reperfusion. Circulation (2004) 1.32
Orai1 and Stim1 regulate normal and hypertrophic growth in cardiomyocytes. J Mol Cell Cardiol (2010) 1.32
Calcium influx through Cav1.2 is a proximal signal for pathological cardiomyocyte hypertrophy. J Mol Cell Cardiol (2010) 1.31
GRK2 as a novel gene therapy target in heart failure. J Mol Cell Cardiol (2010) 1.31
Regulated overexpression of the A1-adenosine receptor in mice results in adverse but reversible changes in cardiac morphology and function. Circulation (2006) 1.30
Differential myocardial gene expression in the development and rescue of murine heart failure. Physiol Genomics (2003) 1.28
Lymphocyte levels of GRK2 (betaARK1) mirror changes in the LVAD-supported failing human heart: lower GRK2 associated with improved beta-adrenergic signaling after mechanical unloading. J Card Fail (2006) 1.28
G protein-coupled receptor internalization signaling is required for cardioprotection in ischemic preconditioning. Circ Res (2004) 1.27
Targeting myocardial beta-adrenergic receptor signaling and calcium cycling for heart failure gene therapy. J Card Fail (2007) 1.27
Comparative cardiac gene delivery of adeno-associated virus serotypes 1-9 reveals that AAV6 mediates the most efficient transduction in mouse heart. Clin Transl Sci (2010) 1.26
GSK-3α is a central regulator of age-related pathologies in mice. J Clin Invest (2013) 1.25
Extracellular S100A1 protein inhibits apoptosis in ventricular cardiomyocytes via activation of the extracellular signal-regulated protein kinase 1/2 (ERK1/2). J Biol Chem (2003) 1.25
G protein-coupled receptor kinase 2 activity impairs cardiac glucose uptake and promotes insulin resistance after myocardial ischemia. Circulation (2011) 1.23